Tao Jie, Shi Xiaoli, Feng Xu, Wu Xinhua, Qi Shiguai, Feng Guoying, Yang Xu, Zhao Yufei, Zuo Hangjia, Shi Zhengrong
Department of General Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Comb Chem High Throughput Screen. 2024;27(8):1111-1118. doi: 10.2174/1386207326666230824090204.
There is a lack of a reliable outcome prediction model for patients evaluating the feasibility of postoperative adjuvant transarterial chemoembolization (PATACE) therapy. Our goal was to develop an easy-to-use tool specifically for these patients.
From January 2013 to June 2017, patients with hepatocellular carcinoma from the Liver Center of the First Affiliated Hospital of Chongqing Medical University received postoperative adjuvant Transarterial chemoembolization (TACE) therapy after liver cancer resection. A Cox proportional hazards model was established for these patients, followed by internal validation (enhanced bootstrap resampling technique) to further evaluate the predictive performance and discriminanceevaluate the predictive performance and discriminance, and compare it with other predictive models. The prognostic factors considered included tumour number, maximum tumor diameter, Edmondson-Steiner (ES) grade, Microvascular invasion (MVI) grade, Ki67, age, sex, hepatitis B surface antigen, cirrhosis, Alpha-fetoprotein (AFP), Albumin-bilirubin (ALBI) grade, Childpugh grade, body mass index (BMI), Neutrophil-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR).
The endpoint of the study was overall survival. The median overall survival was 36 (95%CI: 34.0-38.0) months, with 1-year, 2-year and 3-year survival rates being 96.3%, 84.0% and 75.3%, respectively. Tumour number, MVI grade, and BMI was incorporated into the model, which had good differentiation and accuracy. Internal validation (enhanced bootstrap) suggested that Harrell's C statistic is 0.72. The model consistently outperforms other currently available models.
This model may be an easy-to-use tool for screening patients suitable for PA-TACE treatment and guiding the selection of clinical protocols. But further research and external validation are required.
在评估术后辅助经动脉化疗栓塞术(PATACE)治疗可行性的患者中,缺乏可靠的预后预测模型。我们的目标是为这些患者开发一种易于使用的工具。
2013年1月至2017年6月,重庆医科大学附属第一医院肝脏中心的肝细胞癌患者在肝癌切除术后接受了术后辅助经动脉化疗栓塞术(TACE)治疗。为这些患者建立了Cox比例风险模型,随后进行内部验证(增强型自举重采样技术)以进一步评估预测性能和判别能力,并与其他预测模型进行比较。考虑的预后因素包括肿瘤数量、最大肿瘤直径、埃德蒙森-斯坦纳(ES)分级、微血管侵犯(MVI)分级、Ki67、年龄、性别、乙肝表面抗原、肝硬化、甲胎蛋白(AFP)、白蛋白-胆红素(ALBI)分级、Childpugh分级、体重指数(BMI)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)。
研究终点为总生存期。中位总生存期为36(95%CI:34.0 - 38.0)个月,1年、2年和3年生存率分别为96.3%、84.0%和75.3%。肿瘤数量、MVI分级和BMI被纳入模型,该模型具有良好的区分度和准确性。内部验证(增强型自举)表明Harrell's C统计量为0.72。该模型始终优于其他现有模型。
该模型可能是一种易于使用的工具,用于筛选适合PA - TACE治疗的患者并指导临床方案的选择。但需要进一步的研究和外部验证。